echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Significantly reduce patient recovery time! Fujifilm applied in Japan for approval of the new crown for the treatment of Fabirave.

    Significantly reduce patient recovery time! Fujifilm applied in Japan for approval of the new crown for the treatment of Fabirave.

    • Last Update: 2020-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Fujifilm said on Wednesday it would apply in Japan for its anti-flu drug Avigan, also known as Favipiravir, for the treatment of new crown pneumonia.
    the application is based on a Phase 3 study that showed the drug could help patients with neo-coronary mild recovery more quickly.
    the trial was conducted in 156 patients with neo-coronary pneumonia, who were randomly divided into two groups, one using Avigan and the other using a placebo.
    the Avigan group had an average recovery time of 11.9 days, while in the placebo group 14.7 days, there were no safety problems in the trial.
    , Avigan has been approved in Japan to treat new or relapsed influenza.
    the early stages of the new crown pandemic, Avigan was in the eye after researchers highlighted the potential of anti-flu drugs to fight new coronavirus.
    fujifilm has also been pre-anticipated to start testing and expand production.
    , the company has signed licensing agreements with Dr. Reddy's Laboratories and Global Response Aid to enable production around the world.
    Avigan was first produced by Toyama Chemical, which was acquired in 2008 by Fujifilm, a transformational pharmaceutical company, and its anti-flu drug, Avigan, was included.
    , a leading manufacturer of photographic film in the industry, Fujifilm once outstayed Kodak, reaching a 70% market share in Japan and peaking in 2000.
    in the digital camera age, however, the film industry can not escape the fate.
    began in 2000, Fujifilm began to decline at a negative rate of 20-30% a year, and by 2010 its film business had shrunk to less than 10%.
    Fortunately, Fujifilm early warning, has already begun to rely on its own technology to expand the business, relying on medical health, high-performance materials, printing systems, digital imaging, optical components and document processing six business sectors, in 2007 returned to the high performance.
    as the "film king" of the film industry as early as the 1990s has been involved in drug production, once producing aspirin.
    because the pharmaceutical industry needed long-term research and development investment, Kodak ultimately failed to hold on.
    only in recent years has it returned to the pharmaceutical business and expanded its pharmaceutical plants significantly.
    At the end of July, Kodak received a $765 million loan from the U.S. government to fund its production of raw materials for new crown drugs in the U.S., changing U.S. dependence on foreign production chains, including hydroxychloroquine, an antimalarial drug that Mr. Trump has said can be used to treat coronavirus.
    news, Kodak's share price rose 1167 percent in two days.
    Kodak, which are gradually moving away from the film business, are actively expanding their business to face the outbreak during the New Crown pandemic.
    Fuji betting Fapirave, Kodak started with "hydroxychloroquine."
    how the battle between the two companies will play out in the new pharmaceutical sector remains to be seen.
    source: Fujifilm's flu drug Avigan improves COVID-19 recovery time, set up filing in Japan.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.